# Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

> **NCT00724360** · PHASE2 · TERMINATED · sponsor: **Nantes University Hospital** · enrollment: 15 (actual)

## Conditions studied

- Relapsed/Refractory Leukemia

## Interventions

- **DRUG:** Herceptin (trastuzumab)

## Key facts

- **NCT ID:** NCT00724360
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-11
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Difficulties of recruitment
- **Last updated:** 2013-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724360, "Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00724360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*